Lantern Pharma Inc. (NASDAQ:LTRN) is set to showcase two of its commercially deployed artificial intelligence platforms at the University of North Texas’ inaugural AI for Biology and Medicine (AI4BM) symposium, the biotech company announced Thursday. The event is hosted by Dr. Serdar Bozdag and UNT’s new Center for Computational Life Sciences, and is expected to gather leading researchers working at the intersection of AI and biomedicine.
Lantern will deliver two technical presentations highlighting how its machine-learning systems are reshaping drug discovery and precision oncology—including tools already being used by the company and external pharmaceutical partners.
The first session, “Machine Learning Ensemble Models for In Silico Screening and Prediction of Blood-Brain Barrier Permeability: A Comprehensive Approach Using Molecular Fingerprints and Descriptors,” will detail predictBBB.ai, Lantern’s deployed platform that ranks at the top of the Therapeutic Data Commons leaderboard with 94.1% accuracy. The system can triage 200,000 compounds in under a week and has been blindly validated on more than 1,300 previously unseen molecules, significantly accelerating development of CNS-focused therapeutics.
The second presentation, “Machine Learning Models for Liquid Biopsy-Based Treatment Response Prediction and Biomarker Discovery in Cancer,” will spotlight LBx-AI, a production-ready platform that predicts treatment response in non-small cell lung cancer with 86% accuracy. Using engineered pathway-level features rather than single-mutation analysis, LBx-AI identifies biomarkers that traditional approaches overlook—20 of the 21 most predictive markers surfaced by the model are pathway-derived. The platform can also infer tumor characteristics from circulating tumor DNA, including accurately estimating PD-L1 expression (0.76 Pearson correlation). Ongoing collaborations aim to extend performance across glioblastoma, breast cancer, and additional tumor types.
Lantern says its AI platforms are differentiated by their commercial readiness, scalability, and ability to compress drug development timelines from months or years to mere days. Both models feed into the company’s RADR® ecosystem, with LBx-AI supporting precision oncology efforts and predictBBB.ai offered as a standalone service for CNS drug developers.
“Our team is excited to share our efforts and platforms with leading researchers at this inaugural AI symposium,” said Panna Sharma, President and CEO at Lantern Pharma. “We’re honored to present alongside distinguished researchers and look forward to engaging with the scientific community. Our vision extends beyond these current capabilities—we’re committed to making these powerful AI tools available as open-access platforms, democratizing advanced computational methods for researchers worldwide.”
The symposium will also feature keynote speaker Dr. Iman Hajirasouliha of Weill Cornell Medicine, a leading figure in computational biomedicine and precision oncology.
About Lantern Pharma
Lantern Pharma is an AI-driven biotechnology company developing cancer therapies through its proprietary RADR® drug-discovery platform, which uses machine learning to accelerate development timelines, uncover new therapeutic opportunities, and improve patient outcomes.